

IPO Expected Timetable#

Stock Code	Stock Name	Closing Date*	Allotment Date	Listing Date
09969	INNOCARE-B	2020/03/13	2020/03/20	2020/03/23

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit www.cfs.com.hk or contact our account executives or customer service officers

* Applicants please deposit the full amount / margin into the bank account of Celestial Securities Limited no later than 12:00 p.m. in case of cash payment or 4:00 p.m. in case of cheque payment on the Closing Date. If your margin financing is approved and your application for Public Offer Shares is successful (in whole or in part), please deposit the remaining amount of margin no later than 4:00 p.m. on the allotment date.

InnoCare Pharma Limited (9969.HK)

Share Offer Highlights

Total number of Offer Shares:	250,324,000 Shares (subject to the Overallotment Option)
- Number of Public Offer Shares:	25,034,000 Shares (subject to adjustment)
- Number of Placing Shares:	225,290,000 Shares (subject to adjustment and the Over-allotment Option)
Number of Shares per Lot:	1,000 Shares
Offer Price:	HKD 8.18 – 8.95 per Share
2018 Historical P/E ratio:	-
Sponsor:	Morgan Stanley, Goldman Sachs

Company Overview

The Company is a clinical stage biopharmaceutical company committed to discovering, developing and commercializing potential best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Its drug candidates are targeting both evidence-based and novel biological pathways. Its discovery and development efforts are focused on drug candidates with evidence-based targets that have the potential to be best-in-class from a safety and efficacy perspective. It also devote significant efforts in identifying novel targets and developing therapies with global breakthrough potential. In less than four years, its team has discovered and developed a pipeline of nine drug candidates. Its vision is to become a global biopharmaceutical leader that develops and delivers innovative therapies for patients worldwide.

For the year ended December 31, 2017 and 2018 and the nine months ended September 30, 2019, the Company's net losses were RMB341.73 mn, RMB549.95 mn and RMB651.92 mn respectively.

Source

IPO Prospectus

Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-21) 3227 9888
	Rm 5601, East Tower, Top Plaza, No. 222 Xingmin Road, Zhujiang New Town, Tianhe District, Guangzhou	(86-20) 8362 6610
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026

Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.